Daptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms. Daptomycin was removed from the World Health Organization's List o and is chemically defined as a cyclic anionic lipopeptide of 13 amino acids with an N-terminal decanoyl fatty acyl chain, produced by Streptomyces roseosporus; its molecular weight is approximately 1620 Da. It exhibits rapid, concentration-dependent bactericidal activity against susceptible Gram-positive bacteria including methicillin-resistant Staphylococcus aureus and many enterococci. Activity is calcium dependent and requires drug oligomerization and insertion into the cytoplasmic membrane leading to membrane depolarization, loss of membrane potential, and inhibition of DNA, RNA and protein synthesis. The molecule is heat-stable under standard manufacturing conditions, chemically labile under strong acid or base and susceptible to oxidative and hydrolytic degradation; formulation for intravenous use uses reconstitution buffers to maintain stability and calcium levels that support activity.
Parent: Daptomycin
Parent: Daptomycin
The impurity profile of daptomycin includes process-related and degradation-related species such as deacylated analogs, ring-opened peptides, oxidized tryptophan and methionine residues, desamino or deamidated products, and fatty-acyl chain variants (for example shortened or elongated acyl chains). In well-controlled manufacturing and stability programs, individual related compounds are typically observed at low levels, commonly in the range of less than 0.1 to 0.5 percent relative to the main peak, with some stress or aged samples showing certain degradation products up to about 1.0 percent; total detectable impurities are generally controlled to be below approximately 3.0 percent for release and shelf-life specifications, although exact acceptance criteria are set by the product specification and applicable pharmacopeial monographs. Identification and quantitation are performed by validated chromatographic and mass spectrometric methods and monitored for known genotoxic or pharmacologically relevant species to ensure safety and potency.
Daptomycin is a cyclic lipopeptide antibiotic with bactericidal, concentration-dependent activity against Gram-positive organisms; it is distinct from glycopeptides and other classes by its lipid tail and membrane-targeting mechanism.
No. Daptomycin is not vancomycin. Vancomycin is a glycopeptide that inhibits cell wall synthesis, whereas daptomycin is a lipopeptide that disrupts bacterial membrane potential in a calcium-dependent manner.
Daptomycin is reserved for serious Gram-positive infections, including those caused by resistant organisms, but whether it is deemed a last resort depends on the clinical context, local guidelines and susceptibility patterns; it is often used when infections are refractory to or intolerant of first-line agents.
Daptomycin binds to bacterial membranes in a calcium-dependent fashion, oligomerizes and inserts its lipid tail into the membrane, causing rapid membrane depolarization, disruption of membrane-associated processes and subsequent inhibition of DNA, RNA and protein synthesis leading to cell death.
